← Leaderboards
Shuxia Wang
University Of Kentucky
$5,165,466
Attributed
$5,165,466
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $558.8K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,165,466 · 6
VA$0 · 2
By mechanism
R01$4,535,240 · 3
P20$479,809 · 2
R03$150,417 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingIn VivoIn VitroReceptorSignal TransductionMouse ModelLeadObesityDietProteinsFibrosisMolecularPlayNovel TherapeuticsWild Type MouseProductionKidneyMediator Of Activation ProteinExhibitsObesity TreatmentCellsRodentMacrophageInflammation
Grant awards (27)
Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease$478,167
R01 · FY2025 · DK · contact PI
Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease$459,040
R01 · FY2024 · DK · contact PI
Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations$99,797
R01 · FY2024 · DK · contact PI
Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease$478,167
R01 · FY2023 · DK · contact PI
CD47 as a therapeutic target for obesity$0
I01 · FY2023 · VA · contact PI
Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease$491,417
R01 · FY2022 · DK · contact PI
CD47 as a therapeutic target for obesity$0
I01 · FY2022 · VA · contact PI
CD47 as a therapeutic target for obesity$0
I01 · FY2021 · VA · contact PI
CD47 as a therapeutic target for obesity$0
I01 · FY2020 · VA · contact PI
CD47 as a therapeutic target for obesity$0
I01 · FY2019 · VA · contact PI
Thrombospondin 1 in obesity associated inflammation and insulin resistance$288,843
R01 · FY2017 · DK · contact PI
Thrombospondin 1 in obesity associated inflammation and insulin resistance$303,454
R01 · FY2016 · DK · contact PI
Increasing PKG activity protects aging kidney from ischemic-reperfusion induced injury$75,250
R03 · FY2016 · AG · contact PI
Thrombospondin 1 in obesity associated inflammation and insulin resistance$303,454
R01 · FY2015 · DK · contact PI
Increasing PKG activity protects aging kidney from ischemic-reperfusion induced injury$75,167
R03 · FY2015 · AG · contact PI
Thrombospondin 1 in obesity associated inflammation and insulin resistance$309,065
R01 · FY2014 · DK · contact PI
Renoprotective effect of increased PKG activity in diabetic nephropathy$0
I01 · FY2014 · VA · contact PI
Upstream Stimulatory Factor 2 regulation of renin in diabetic nephropathy$241,092
R01 · FY2013 · DK · contact PI
Renoprotective effect of increased PKG activity in diabetic nephropathy$0
I01 · FY2013 · VA · contact PI
Upstream Stimulatory Factor 2 regulation of renin in diabetic nephropathy$249,837
R01 · FY2012 · DK · contact PI
Renoprotective effect of increased PKG activity in diabetic nephropathy$0
I01 · FY2012 · VA · contact PI
Upstream Stimulatory Factor 2 regulation of renin in diabetic nephropathy$249,837
R01 · FY2011 · DK · contact PI
Renoprotective effect of increased PKG activity in diabetic nephropathy$0
I01 · FY2011 · VA · contact PI
Upstream Stimulatory Factor 2 regulation of renin in diabetic nephropathy$290,070
R01 · FY2010 · DK · contact PI
THROMBOSPONDIN1 MEDIATES MACROPHAGE INFILTRATION INTO ADIPOSE TISSUE AND PROMOTE$248,383
P20 · FY2010 · RR · contact PI
Upstream Stimulatory Factor 2 regulation of renin in diabetic nephropathy$293,000
R01 · FY2009 · DK · contact PI
THROMBOSPONDIN 1 MEDIATES MACROPHAGE INFILTRATION INTO ADIPOSE TISSUE AND PROMOT$231,426
P20 · FY2009 · RR · contact PI